Alexion Pharmaceuticals (ALXN) Receiving Somewhat Favorable News Coverage, Analysis Shows
Media coverage about Alexion Pharmaceuticals (NASDAQ:ALXN) has trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Alexion Pharmaceuticals earned a news impact score of 0.12 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.2399380990255 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Alexion Pharmaceuticals, Inc., (NASDAQ: ALXN), The Goldman Sachs Group, Inc., (NYSE: GS), British American … – Stocks In The News (press release) (tradingnewsnow.com)
- ETFs with exposure to Alexion Pharmaceuticals, Inc. : November 27, 2017 (finance.yahoo.com)
- Alexion Pharmaceuticals : to Present at the Citi 2017 Global Healthcare Conference (4-traders.com)
- Today’s Research Reports on Trending Tickers: Acorda Therapeutics and Alexion Pharmaceuticals (finance.yahoo.com)
- Alexion to Present at the Citi 2017 Global Healthcare Conference (finance.yahoo.com)
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up $1.01 during midday trading on Monday, reaching $108.61. The company’s stock had a trading volume of 662,400 shares, compared to its average volume of 2,287,017. The firm has a market capitalization of $24,260.00, a P/E ratio of 22.21, a PEG ratio of 1.18 and a beta of 1.22. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals has a 1 year low of $96.18 and a 1 year high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. During the same quarter in the prior year, the business earned $1.23 earnings per share. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. equities analysts forecast that Alexion Pharmaceuticals will post 4.81 EPS for the current fiscal year.
Several research analysts have recently issued reports on ALXN shares. Zacks Investment Research lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Royal Bank Of Canada lifted their target price on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Piper Jaffray Companies reiterated an “overweight” rating and set a $170.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, October 23rd. TheStreet lowered Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. Finally, Stifel Nicolaus reduced their target price on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a report on Tuesday, October 24th. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $154.01.
In other Alexion Pharmaceuticals news, EVP Julie O’neill sold 4,375 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total transaction of $636,300.00. Following the completion of the sale, the executive vice president now directly owns 26,092 shares in the company, valued at $3,794,820.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the sale, the director now owns 5,480 shares of the company’s stock, valued at $799,038.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,330 shares of company stock valued at $774,851. 4.35% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Alexion Pharmaceuticals (ALXN) Receiving Somewhat Favorable News Coverage, Analysis Shows” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/alexion-pharmaceuticals-alxn-receiving-somewhat-favorable-news-coverage-analysis-shows/1729718.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.